ClinicalTrials.gg
TerminatedNCT05746559ARTEMISUpdated Oct 29, 2026Results posted

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

A Phase 3 interventional study of Placebo and Ravulizumab in Chronic Kidney Disease, CKD and Cardiac Disease, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 130 sites in 20 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Why this study was terminated
The ALXN1210-CSA-AKI-318 trial was discontinued on 29-Apr-2026 due to lack of efficacy in this overall study universe / patient population.
Updated Oct 29, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
555
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Renal Insufficiency, Chronic by AstraZeneca — 6 open to participants now, 11 under way, 5 of them phase 3. Renal Insufficiency, Chronic · AstraZeneca.

Enrollment
12th of 38
555 · median 170
Started
2023
with 4 others
Phase 3
10 of 54
3 open now
Registered
31st of 54
by date

Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, this one is the 12th largest by enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2023, is one of 10 in phase 3, and was the 31st registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 54 studies in Renal Insufficiency, Chronic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Renal Insufficiency, Chronic by AstraZeneca, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.

03

Conditions studied

  • Chronic Kidney Disease
  • CKD
  • Cardiac Disease
  • Cardiopulmonary Bypass

Keywords

  • Chronic Kidney Disease
  • CKD
  • Cardiac Disease
  • Cardiopulmonary Bypass
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant weighs ≥ 30 kg
  • Planned non-emergent sternotomy with CPB procedure for the following surgeries:
  • Multi-vessel CABG
  • Valve replacement or repair; ascending aorta surgery permitted if combined with aortic valve replacement/repair
  • Combined CABG and valve surgery; inclusion of single-vessel CABG when combined with valve replacement/repair is permitted
  • Known CKD for at least 90 days (CKD Stage 3A, 3B, or 4)

Exclusion criteria

Exclusion Criteria:

  • Emergency or salvage cardiac surgery is expected at screening or randomization, as assessed by the investigator.
  • Single-vessel CABG without valve surgery is planned.
  • Off-pump surgery is planned (eg, surgery without CPB).
  • Recipient of a solid organ or bone marrow transplantation.
  • Cardiogenic shock, hemodynamic instability, use of intra-aortic balloon pump, extracorporeal membrane oxygenation, or left ventricular assist device within 72 hours of randomization.
  • Active systemic bacterial, viral, or fungal infection within 14 days prior to randomization.
  • History of unexplained, recurrent infection.
  • Any use of KRT or presence of AKI within 30 days of randomization
  • Use of any complement inhibitors, or plasmapheresis or plasma exchange within the year prior to Screening, or planned use during the course of the study.
  • Participant is not willing to be vaccinated against N meningitidis or is unwilling to receive prophylactic treatment with appropriate antibiotics , if needed
  • History of or unresolved N meningitidis infection.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
555 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive a single weight-based dose of placebo via intravenous infusion, 1 to 7 days prior to surgery.

    Drug: Placebo

  • Experimental
    Ravulizumab

    Participants will receive a single weight-based dose of ravulizumab, via intravenous infusion, 1 to 7 days prior to surgery.

    Drug: Ravulizumab

Interventions

  • DrugPlacebo

    Participants will receive a single weight-based dose of placebo via intravenous infusion.

  • Participants will receive a single weight-based dose of ravulizumab via intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Estimated Percentage of Participants Who Experienced Major Adverse Kidney Events (MAKE, Based on Serum Cystatin C [sCysC)] at Day 90 Post-CPB (MAKE90)

    MAKE90 was defined as meeting at least one of the following three criteria: * Decrease from baseline in estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula using sCysC) of ≥ 25% at Day 90 post CPB, * Initiation of kidney replacement therapy (KRT) through Day 90 post CPB, or * Death from any cause through Day 90 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of missing at random (MAR).

    Time frame: Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

Secondary outcomes

  1. Estimated Percentage of Participants With Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) Without Recovery at Day 90 Post-CPB

    CSA-AKI without recovery was defined as experiencing CSA-AKI based on highest observed serum creatinine (sCr) from randomization to Day 7 post CPB and had occurrence of non-recovered (complete \[sCr \< 1.1\*baseline\] or partial \[sCr ≥ 1.1 to \< 1.5\*baseline\]) CSA-AKI at Day 90. The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 7 days after surgery with CPB, based on the modified Kidney Disease: Improving Global Outcomes (nonprofit foundation, KDIGO) criteria: * An increase in sCr by ≥ 0.3 milligrams per deciliter (mg/dL) in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.

    Time frame: Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  2. Estimated Percentage of Participants With Severe CSA-AKI (KDIGO Stage 2 or 3)

    Occurrence of severe CSA-AKI from randomization to Day 7 and Day 30 post-CPB was defined as meeting KDIGO stage 2 or 3 based on the highest observed sCr from randomization to Day 7 and Day 30 post-CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events. CSA-AKI Staging by Modified KDIGO Criteria: * AKI Stage 1 - An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or an increase in sCr to ≥ 1.5 to \< 2.0\*baseline. * AKI Stage 2 - An increase in sCr to ≥ 2.0 to \< 3.0\*baseline. * AKI Stage 3 - An increase in sCr to ≥ 3.0\*baseline, or an increase in sCr to ≥ 4.0 mg/dL in participants meeting AKI criteria, or initiation of KRT.

    Time frame: From randomization to Days 7 and 30 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  3. Estimated Percentage of Participants Who Died or Required KRT From Randomization to Day 90 Post-CPB

    Estimated percentages were calculated using imputation of missing data. Missing data for the death component were addressed using a multiple imputation approach under the assumption of MAR. Missing values for the KRT component were imputed as non-events.

    Time frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  4. Estimated All-cause Mortality From Randomization to Day 90 Post-CPB

    Estimated all-cause mortality data (estimated percentage of participants who died) from randomization to Day 90 post-CPB is reported in this outcome measure. Estimated percentages were calculated using imputation of missing data. Missing data for death were addressed using a multiple imputation approach under the assumption of MAR. A summary of all-cause mortality through to the end of the study, without imputation for missing data, is located in the 'Reported Adverse Events' Section.

    Time frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  5. Estimated Median Length of Post-operative Intensive Care Unit (ICU) Stay

    The length of post-operative ICU stay was calculated based on the date/time of post-operative ICU discharge - the date/time of post-operative ICU admission for a participant who was admitted to ICU post-surgery and was alive at ICU discharge. Estimated medians were calculated using imputation of missing data. Missing length of post-operative ICU stay was imputed by the worst value due to death and median of all participants due to other reasons.

    Time frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  6. Estimated Percentage of Participants Who Experienced MAKE at Day 30 (MAKE30) and Day 60 (MAKE60) Post-CPB Based on sCysC

    MAKE30 and MAKE60 were defined as meeting at least one of the following criteria: * Decrease from baseline in eGFR (CKD-EPI formula using sCysC) of ≥ 25% at Day 30 or 60 post CPB, * Initiation of KRT through Days 30 or 60 post CPB, or * Death from any cause through Days 30 or 60 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.

    Time frame: Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  7. Estimated Percentage of Participants Who Experienced MAKE30, MAKE60, and MAKE90 Post-CPB Based on sCr

    MAKE30, MAKE60 and MAKE90 were defined as meeting at least one of the following three criteria: * Decrease from baseline in eGFR (CKD-EPI formula using sCr) of ≥ 25% at Days 30, 60, or 90 post CPB, * Initiation of KRT through Days 30, 60, or 90 post CPB, or * Death from any cause through Days 30, 60, or 90 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.

    Time frame: Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  8. MAKE Components: Estimated Percentage of Participants Who Died From Randomization Through Days 30, 60, and 90

    The estimated percentage of participants who died from any cause from randomization through Days 30, 60, or 90 are reported. Note that data imputation for this outcome measure is different than the imputation for the 'All-cause Mortality' outcome measure. Missing data for this outcome measure were imputed as non-events. A summary of all-cause mortality through to the end of the study, without imputation for missing data, is located in the 'Reported Adverse Events' Section.

    Time frame: From randomization to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  9. MAKE Components: Estimated Percentage of Participants With Initiation of KRT

    Estimated percentage of participants with initiation of KRT through Days 30, 60, or 90 post-CPB are reported. Estimated percentages were calculated using imputation of missing data. Missing data were imputed as non-events.

    Time frame: From randomization to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  10. MAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCysC

    Estimated percentage of participants with a decrease from baseline in eGFR (CKD-EPI formula using sCysC) of ≥ 25% at Days 30 or 60 post-CPB is reported. Estimated percentages were calculated using imputation of missing data. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.

    Time frame: Baseline to Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  11. MAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCr

    Estimated percentage of participants with a decrease from baseline in eGFR (CKD-EPI formula using sCr) of ≥ 25% at Days 30, 60, or 90 post-CPB is reported. Estimated percentages were calculated using imputation of missing data. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.

    Time frame: Baseline to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  12. Estimated Percentage of Participants Who Died or Required KRT From Randomization to Days 30 and 60 Post-CPB

    Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events.

    Time frame: From randomization to Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  13. Estimated Percentage of Participants With Post-Operative Renal Failure

    Post-operative renal failure was a Society of Thoracic Surgeons (STS) metric based on modified Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) failure creatinine criteria and was defined as: * An increase in sCr to ≥ 3.0\*baseline, * An increase in sCr to ≥ 4.0 mg/dL with an increase of at least 0.5 mg/dL from baseline, or * Initiation of KRT. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.

    Time frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  14. Number of Participants With Highest CSA-AKI Stage (Modified KDIGO Criteria) Based on sCr

    The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 3 or 7 days after surgery with CPB, based on the modified KDIGO criteria: * An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. CSA-AKI Staging by Modified KDIGO Criteria: * AKI Stage 1 - An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or an increase in sCr to ≥ 1.5 to \< 2.0\*baseline. * AKI Stage 2 - An increase in sCr to ≥ 2.0 to \< 3.0\*baseline. * AKI Stage 3 - An increase in sCr to ≥ 3.0\*baseline, or an increase in sCr to ≥ 4.0 mg/dL in participants meeting AKI criteria, or initiation of KRT.

    Time frame: Within 3 and 7 Days Post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  15. Estimated Percentage of Participants With CSA-AKI Without Recovery at Days 15, 30, and 60 Post-CPB

    CSA-AKI without recovery was defined as experiencing CSA-AKI based on highest observed sCr from randomization to Day 7 post CPB and had occurrence of non-recovered (complete \[sCr \< 1.1\*baseline\] or partial \[sCr ≥ 1.1 to \< 1.5\*baseline\]) CSA-AKI at Days 15, 30, or 60. The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 7 days after surgery with CPB, based on the KDIGO criteria: * An increase in sCr by ≥ 0.3 milligrams per deciliter (mg/dL) in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.

    Time frame: Days 15, 30, and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  16. Estimated Percentage of Participants With AKI at Days 3, 7, 15, 30, 60, and 90 Post-CPB

    AKI was defined as sCr \> 1.5\*baseline at Days 3, 7, 15, 30, 60, and 90 post-CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.

    Time frame: Days 3, 7, 15, 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

  17. Number of Participants With AKI Progression on Days 15, 30, 60, and 90 Post-CPB for Those Experiencing CSA-AKI Within 7 Days Post-CPB

    Occurrence of post-operative CSA-AKI was using modified KDIGO criteria within 7 days after CPB: An increase in sCr by ≥0.3 mg/dL in a 48-hour period or ≥1.5\*baseline within the 7 days following CPB. Stages of post-CSA-AKI kidney function to determine AKI progression: * Post-AKI stage 0 - Complete recovery: sCr \<1.1\*baseline or partial recovery: sCr ≥1.1 to \<1.5 × baseline; * Post-AKI Stage 1 - sCr ≥1.5 to \<2.0\*baseline; * Post-AKI Stage 2 - sCr ≥2.0 - \<3.0\*baseline; * Post-AKI Stage 3 - sCr ≥3.0\*baseline, or sCr ≥4.0 mg/dL in participants meeting CSA-AKI criteria or KRT. AKI progression: * AKI recovery - Complete: sCr \<1.1\*baseline or Partial: sCr ≥1.1 - \<1.5\*baseline * AKI improvement - Move down 1 or more stages from the highest CSA-AKI stage, or remained in stage 3 but discontinued KRT; * Stable AKI - Unchanged AKI or KRT status; * Worsening AKI - Moved up 1 or more stages from the highest CSA-AKI stage, or Remained in Stage 3 but initiated KRT.

    Time frame: Days 15, 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

07

Results

Posted Oct 29, 2026
Limitations and caveats
The ALXN1210-CSA-AKI-318 trial was discontinued on 29-Apr-2026 due to lack of efficacy in this overall study universe / patient population.

Participant flow

Primary Evaluation Period
Participant flow — Primary Evaluation Period
MilestoneRavulizumabPlacebo
Started278277
Received at least 1 dose of study treatment276273
Completed231251
Not completed4726
Withdrew: Withdrawal by subject106
Withdrew: Death3320
Withdrew: Other than specified10
Withdrew: Physician decision10
Withdrew: Lost to follow-up20
Survival Follow-up Period
Participant flow — Survival Follow-up Period
MilestoneRavulizumabPlacebo
Started235251
Completed153153
Not completed8298
Withdrew: Study termination8298

Outcome measures

PrimaryEstimated Percentage of Participants Who Experienced Major Adverse Kidney Events (MAKE, Based on Serum Cystatin C [sCysC)] at Day 90 Post-CPB (MAKE90)

MAKE90 was defined as meeting at least one of the following three criteria: * Decrease from baseline in estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula using sCysC) of ≥ 25% at Day 90 post CPB, * Initiation of kidney replacement therapy (KRT) through Day 90 post CPB, or * Death from any cause through Day 90 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of missing at random (MAR).

Time frame:
Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
Estimated Percentage of Participants Who Experienced Major Adverse Kidney Events (MAKE, Based on Serum Cystatin C [sCysC)] at Day 90 Post-CPB (MAKE90)
percentage of participantsRavulizumabPlacebo
Estimated Percentage of Participants Who Experienced Major Adverse Kidney Events (MAKE, Based on Serum Cystatin C [sCysC)] at Day 90 Post-CPB (MAKE90)35.033.2
Statistical analysis
  • Ravulizumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.6651 · Rate difference: 1.8 · 95% CI -6.4 to 10.0
SecondaryEstimated Percentage of Participants With Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) Without Recovery at Day 90 Post-CPB

CSA-AKI without recovery was defined as experiencing CSA-AKI based on highest observed serum creatinine (sCr) from randomization to Day 7 post CPB and had occurrence of non-recovered (complete \[sCr \< 1.1\*baseline\] or partial \[sCr ≥ 1.1 to \< 1.5\*baseline\]) CSA-AKI at Day 90. The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 7 days after surgery with CPB, based on the modified Kidney Disease: Improving Global Outcomes (nonprofit foundation, KDIGO) criteria: * An increase in sCr by ≥ 0.3 milligrams per deciliter (mg/dL) in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.

Time frame:
Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
Estimated Percentage of Participants With Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) Without Recovery at Day 90 Post-CPB
percentage of participantsRavulizumabPlacebo
Estimated Percentage of Participants With Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) Without Recovery at Day 90 Post-CPB2.52.2
Statistical analysis
  • Ravulizumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.7860 · Rate difference: 0.3 · 95% CI -2.2 to 2.9Nominal p-value presented due to failure of testing hierarchy.
SecondaryEstimated Percentage of Participants With Severe CSA-AKI (KDIGO Stage 2 or 3)

Occurrence of severe CSA-AKI from randomization to Day 7 and Day 30 post-CPB was defined as meeting KDIGO stage 2 or 3 based on the highest observed sCr from randomization to Day 7 and Day 30 post-CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events. CSA-AKI Staging by Modified KDIGO Criteria: * AKI Stage 1 - An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or an increase in sCr to ≥ 1.5 to \< 2.0\*baseline. * AKI Stage 2 - An increase in sCr to ≥ 2.0 to \< 3.0\*baseline. * AKI Stage 3 - An increase in sCr to ≥ 3.0\*baseline, or an increase in sCr to ≥ 4.0 mg/dL in participants meeting AKI criteria, or initiation of KRT.

Time frame:
From randomization to Days 7 and 30 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
Estimated Percentage of Participants With Severe CSA-AKI (KDIGO Stage 2 or 3)
percentage of participantsRavulizumabPlacebo
Day 7 Post-CPB15.117.3
Day 30 Post-CPB14.719.5
Statistical analysis
  • Ravulizumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.4654 (Nominal p-value presented due to failure of testing hierarchy.) · Rate difference: -2.2 · 95% CI -8.3 to 3.8
  • Ravulizumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.1306 (Nominal p-value presented due to failure of testing hierarchy.) · Rate difference: -4.8 · 95% CI -11.0 to 1.4
SecondaryEstimated Percentage of Participants Who Died or Required KRT From Randomization to Day 90 Post-CPB

Estimated percentages were calculated using imputation of missing data. Missing data for the death component were addressed using a multiple imputation approach under the assumption of MAR. Missing values for the KRT component were imputed as non-events.

Time frame:
From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
Estimated Percentage of Participants Who Died or Required KRT From Randomization to Day 90 Post-CPB
percentage of participantsRavulizumabPlacebo
Estimated Percentage of Participants Who Died or Required KRT From Randomization to Day 90 Post-CPB16.218.9
Statistical analysis
  • Ravulizumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.3943 (Nominal p-value presented due to failure of testing hierarchy.) · Rate difference: -2.8 · 95% CI -9.1 to 3.6
SecondaryEstimated All-cause Mortality From Randomization to Day 90 Post-CPB

Estimated all-cause mortality data (estimated percentage of participants who died) from randomization to Day 90 post-CPB is reported in this outcome measure. Estimated percentages were calculated using imputation of missing data. Missing data for death were addressed using a multiple imputation approach under the assumption of MAR. A summary of all-cause mortality through to the end of the study, without imputation for missing data, is located in the 'Reported Adverse Events' Section.

Time frame:
From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
Estimated All-cause Mortality From Randomization to Day 90 Post-CPB
percentage of participantsRavulizumabPlacebo
Estimated All-cause Mortality From Randomization to Day 90 Post-CPB12.37.4
Statistical analysis
  • Ravulizumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.0585 (Nominal p-value presented due to failure of testing hierarchy.) · Rate difference: 4.8 · 95% CI -0.2 to 9.9
SecondaryEstimated Median Length of Post-operative Intensive Care Unit (ICU) Stay

The length of post-operative ICU stay was calculated based on the date/time of post-operative ICU discharge - the date/time of post-operative ICU admission for a participant who was admitted to ICU post-surgery and was alive at ICU discharge. Estimated medians were calculated using imputation of missing data. Missing length of post-operative ICU stay was imputed by the worst value due to death and median of all participants due to other reasons.

Time frame:
From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Median · hours
Estimated Median Length of Post-operative Intensive Care Unit (ICU) Stay
hoursRavulizumabPlacebo
Estimated Median Length of Post-operative Intensive Care Unit (ICU) Stay67.700 (27.300 to 123.000)75.100 (42.050 to 132.050)
Statistical analysis
  • Ravulizumab vs Placebo · Cochran-Mantel-Haenszel · p = 0.4945 (Nominal p-value presented due to failure of testing hierarchy.) · Median difference: -1.7 · 95% CI -16.2 to 6.2
SecondaryEstimated Percentage of Participants Who Experienced MAKE at Day 30 (MAKE30) and Day 60 (MAKE60) Post-CPB Based on sCysC

MAKE30 and MAKE60 were defined as meeting at least one of the following criteria: * Decrease from baseline in eGFR (CKD-EPI formula using sCysC) of ≥ 25% at Day 30 or 60 post CPB, * Initiation of KRT through Days 30 or 60 post CPB, or * Death from any cause through Days 30 or 60 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.

Time frame:
Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
Estimated Percentage of Participants Who Experienced MAKE at Day 30 (MAKE30) and Day 60 (MAKE60) Post-CPB Based on sCysC
percentage of participantsRavulizumabPlacebo
MAKE3032.633.9
MAKE6030.531.9
SecondaryEstimated Percentage of Participants Who Experienced MAKE30, MAKE60, and MAKE90 Post-CPB Based on sCr

MAKE30, MAKE60 and MAKE90 were defined as meeting at least one of the following three criteria: * Decrease from baseline in eGFR (CKD-EPI formula using sCr) of ≥ 25% at Days 30, 60, or 90 post CPB, * Initiation of KRT through Days 30, 60, or 90 post CPB, or * Death from any cause through Days 30, 60, or 90 post CPB. Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.

Time frame:
Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
Estimated Percentage of Participants Who Experienced MAKE30, MAKE60, and MAKE90 Post-CPB Based on sCr
percentage of participantsRavulizumabPlacebo
MAKE3026.725.0
MAKE6024.023.9
MAKE9025.624.8
SecondaryMAKE Components: Estimated Percentage of Participants Who Died From Randomization Through Days 30, 60, and 90

The estimated percentage of participants who died from any cause from randomization through Days 30, 60, or 90 are reported. Note that data imputation for this outcome measure is different than the imputation for the 'All-cause Mortality' outcome measure. Missing data for this outcome measure were imputed as non-events. A summary of all-cause mortality through to the end of the study, without imputation for missing data, is located in the 'Reported Adverse Events' Section.

Time frame:
From randomization to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
MAKE Components: Estimated Percentage of Participants Who Died From Randomization Through Days 30, 60, and 90
percentage of participantsRavulizumabPlacebo
Day 3010.16.2
Day 6011.56.9
Day 9011.97.2
SecondaryMAKE Components: Estimated Percentage of Participants With Initiation of KRT

Estimated percentage of participants with initiation of KRT through Days 30, 60, or 90 post-CPB are reported. Estimated percentages were calculated using imputation of missing data. Missing data were imputed as non-events.

Time frame:
From randomization to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
MAKE Components: Estimated Percentage of Participants With Initiation of KRT
percentage of participantsRavulizumabPlacebo
Day 3010.814.8
Day 6011.115.2
Day 9011.115.2
SecondaryMAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCysC

Estimated percentage of participants with a decrease from baseline in eGFR (CKD-EPI formula using sCysC) of ≥ 25% at Days 30 or 60 post-CPB is reported. Estimated percentages were calculated using imputation of missing data. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.

Time frame:
Baseline to Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
MAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCysC
percentage of participantsRavulizumabPlacebo
Day 3023.924.1
Day 6020.220.1
SecondaryMAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCr

Estimated percentage of participants with a decrease from baseline in eGFR (CKD-EPI formula using sCr) of ≥ 25% at Days 30, 60, or 90 post-CPB is reported. Estimated percentages were calculated using imputation of missing data. Missing eGFR values were addressed using a two-step multiple imputation approach under the assumption of MAR.

Time frame:
Baseline to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
MAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCr
percentage of participantsRavulizumabPlacebo
Day 3017.211.7
Day 6011.78.0
Day 9013.19.9
SecondaryEstimated Percentage of Participants Who Died or Required KRT From Randomization to Days 30 and 60 Post-CPB

Estimated percentages were calculated using imputation of missing data. Missing data for KRT initiation or death were imputed as non-events.

Time frame:
From randomization to Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
Estimated Percentage of Participants Who Died or Required KRT From Randomization to Days 30 and 60 Post-CPB
percentage of participantsRavulizumabPlacebo
Day 3014.418.1
Day 6015.518.8
SecondaryEstimated Percentage of Participants With Post-Operative Renal Failure

Post-operative renal failure was a Society of Thoracic Surgeons (STS) metric based on modified Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) failure creatinine criteria and was defined as: * An increase in sCr to ≥ 3.0\*baseline, * An increase in sCr to ≥ 4.0 mg/dL with an increase of at least 0.5 mg/dL from baseline, or * Initiation of KRT. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.

Time frame:
From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
Estimated Percentage of Participants With Post-Operative Renal Failure
percentage of participantsRavulizumabPlacebo
Estimated Percentage of Participants With Post-Operative Renal Failure12.618.1
SecondaryNumber of Participants With Highest CSA-AKI Stage (Modified KDIGO Criteria) Based on sCr

The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 3 or 7 days after surgery with CPB, based on the modified KDIGO criteria: * An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. CSA-AKI Staging by Modified KDIGO Criteria: * AKI Stage 1 - An increase in sCr by ≥ 0.3 mg/dL in a 48-hour period, or an increase in sCr to ≥ 1.5 to \< 2.0\*baseline. * AKI Stage 2 - An increase in sCr to ≥ 2.0 to \< 3.0\*baseline. * AKI Stage 3 - An increase in sCr to ≥ 3.0\*baseline, or an increase in sCr to ≥ 4.0 mg/dL in participants meeting AKI criteria, or initiation of KRT.

Time frame:
Within 3 and 7 Days Post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Count of participants · Participants
Number of Participants With Highest CSA-AKI Stage (Modified KDIGO Criteria) Based on sCr
ParticipantsRavulizumabPlacebo
Highest CSA-AKI Stage Within 3 Days Post-CPB — Stage 1100110
Highest CSA-AKI Stage Within 3 Days Post-CPB — Stage 236
Highest CSA-AKI Stage Within 3 Days Post-CPB — Stage 33038
Highest CSA-AKI Stage Within 7 Days Post-CPB — Stage 1141148
Highest CSA-AKI Stage Within 7 Days Post-CPB — Stage 244
Highest CSA-AKI Stage Within 7 Days Post-CPB — Stage 33843
SecondaryEstimated Percentage of Participants With CSA-AKI Without Recovery at Days 15, 30, and 60 Post-CPB

CSA-AKI without recovery was defined as experiencing CSA-AKI based on highest observed sCr from randomization to Day 7 post CPB and had occurrence of non-recovered (complete \[sCr \< 1.1\*baseline\] or partial \[sCr ≥ 1.1 to \< 1.5\*baseline\]) CSA-AKI at Days 15, 30, or 60. The occurrence of post-operative CSA-AKI was defined as the presence of one of the following two observations during the 7 days after surgery with CPB, based on the KDIGO criteria: * An increase in sCr by ≥ 0.3 milligrams per deciliter (mg/dL) in a 48-hour period, or * An increase in sCr to ≥ 1.5\*baseline within the 7 days following CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.

Time frame:
Days 15, 30, and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
Estimated Percentage of Participants With CSA-AKI Without Recovery at Days 15, 30, and 60 Post-CPB
percentage of participantsRavulizumabPlacebo
Day 157.57.9
Day 305.05.1
Day 601.81.4
SecondaryEstimated Percentage of Participants With AKI at Days 3, 7, 15, 30, 60, and 90 Post-CPB

AKI was defined as sCr \> 1.5\*baseline at Days 3, 7, 15, 30, 60, and 90 post-CPB. Estimated percentages were calculated using imputation of missing data. Missing values were imputed as non-events.

Time frame:
Days 3, 7, 15, 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Number · percentage of participants
Estimated Percentage of Participants With AKI at Days 3, 7, 15, 30, 60, and 90 Post-CPB
percentage of participantsRavulizumabPlacebo
Day 320.925.3
Day 710.410.1
Day 158.68.3
Day 305.75.4
Day 602.91.8
Day 903.23.2
SecondaryNumber of Participants With AKI Progression on Days 15, 30, 60, and 90 Post-CPB for Those Experiencing CSA-AKI Within 7 Days Post-CPB

Occurrence of post-operative CSA-AKI was using modified KDIGO criteria within 7 days after CPB: An increase in sCr by ≥0.3 mg/dL in a 48-hour period or ≥1.5\*baseline within the 7 days following CPB. Stages of post-CSA-AKI kidney function to determine AKI progression: * Post-AKI stage 0 - Complete recovery: sCr \<1.1\*baseline or partial recovery: sCr ≥1.1 to \<1.5 × baseline; * Post-AKI Stage 1 - sCr ≥1.5 to \<2.0\*baseline; * Post-AKI Stage 2 - sCr ≥2.0 - \<3.0\*baseline; * Post-AKI Stage 3 - sCr ≥3.0\*baseline, or sCr ≥4.0 mg/dL in participants meeting CSA-AKI criteria or KRT. AKI progression: * AKI recovery - Complete: sCr \<1.1\*baseline or Partial: sCr ≥1.1 - \<1.5\*baseline * AKI improvement - Move down 1 or more stages from the highest CSA-AKI stage, or remained in stage 3 but discontinued KRT; * Stable AKI - Unchanged AKI or KRT status; * Worsening AKI - Moved up 1 or more stages from the highest CSA-AKI stage, or Remained in Stage 3 but initiated KRT.

Time frame:
Days 15, 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Reported as:
Count of participants · Participants
Number of Participants With AKI Progression on Days 15, 30, 60, and 90 Post-CPB for Those Experiencing CSA-AKI Within 7 Days Post-CPB
ParticipantsRavulizumabPlacebo
Day 15 — Complete Recovery45
Day 15 — Partial Recovery14
Day 15 — Improvement23
Day 15 — Stable142158
Day 15 — Worsening55
Day 30 — Complete Recovery67
Day 30 — Partial Recovery07
Day 30 — Improvement02
Day 30 — Stable138151
Day 30 — Worsening75
Day 60 — Complete Recovery410
Day 60 — Partial Recovery35
Day 60 — Improvement01
Day 60 — Stable133140
Day 60 — Worsening33
Day 90 — Complete Recovery714
Day 90 — Partial Recovery01
Day 90 — Improvement02
Day 90 — Stable126147
Day 90 — Worsening11

Adverse events

Collected over All-cause mortality was collected up to a maximum of 15 months post-CPB. Serious and other adverse events were collected until end of Primary Evaluation Period (up to a maximum duration of up to 90 days post-CPB). Surgery with CPB was within 7 days after study drug administration on Day 1.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ravulizumab39/278 (14%)133/276 (48.2%)220/276 (79.7%)
Placebo29/277 (10.5%)141/273 (51.6%)229/273 (83.9%)
Most frequent serious events
Showing 10 of 251
Most frequent serious events
EventRavulizumabPlacebo
Acute kidney injuryRenal and urinary disorders18/27620/273
Cardiogenic shockCardiac disorders13/2766/273
Pericardial effusionCardiac disorders13/2763/273
Pleural effusionRespiratory, thoracic and mediastinal disorders7/27612/273
PneumoniaInfections and infestations11/2766/273
Postoperative wound infectionInfections and infestations9/2764/273
Cardiac arrestCardiac disorders4/2767/273
Cerebrovascular accidentNervous system disorders4/2767/273
Cardiac failureCardiac disorders7/2766/273
Cardiac failure acuteCardiac disorders7/2761/273
Most frequent other events
Showing 10 of 19
Most frequent other events
EventRavulizumabPlacebo
AnaemiaBlood and lymphatic system disorders54/27649/273
Atrial fibrillationCardiac disorders45/27642/273
Acute kidney injuryRenal and urinary disorders35/27638/273
Pleural EffusionRespiratory, thoracic and mediastinal disorders27/27638/273
Oedema peripheralGeneral disorders31/27627/273
HyperkalaemiaMetabolism and nutrition disorders17/27630/273
NauseaGastrointestinal disorders13/27629/273
HypocalcaemiaMetabolism and nutrition disorders26/27628/273
ThrombocytopeniaBlood and lymphatic system disorders18/27627/273
DeliriumPsychiatric disorders16/27627/273

Baseline characteristics

Intent-to-treat (ITT) Analysis Set included all participants randomized to study intervention. Because participants received weight-based dosing, data were collected by randomized study arm regardless of the actual dose received. Per local law, race and ethnicity data were not collected for participants located in France.

Age, Continuous
Age, Continuous(years)RavulizumabPlaceboTotal
Mean71.1 ± 8.1270.9 ± 8.4371.0 ± 8.27
Sex: Female, Male
Sex: Female, Male(Participants)RavulizumabPlaceboTotal
Female7779156
Male201198399
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RavulizumabPlaceboTotal
Asian4458102
Black or African American71118
White174164338
Not Reported101
Multiple Race473784
Other Than Specified235
Not Collectable347
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RavulizumabPlaceboTotal
Hispanic or Latino455297
Not Hispanic or Latino225215440
Not Reported347
Unknown224
Not Collectable347
08

Study locations

130 sites
  • Research Site
    Orange, California 92868, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Springfield, Massachusetts 01107, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Rochester, New York 14621, United States
  • Research Site
    Valhalla, New York 10595, United States
  • Research Site
    Fargo, North Dakota 58102, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Richmond, Virginia 23298, United States
  • Research Site
    Seattle, Washington 98195, United States
  • Research Site
    Buenos Aires, C1180AAV, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1199ABB, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1428, Argentina
  • Research Site
    Corrientes, W3400AMZ, Argentina
  • Research Site
    Santa Fe, S3000EOM, Argentina
  • Research Site
    Brisbane, 4102, Australia
  • Research Site
    Monash, Australia
  • Research Site
    Murdoch, 6150, Australia
  • Research Site
    Southport, 4215, Australia
  • Research Site
    Belo Horizonte, 30150-221, Brazil
  • Research Site
    Fortaleza, 60430-375, Brazil
  • Research Site
    Recife, 50070-550, Brazil
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
  • Research Site
    Rio de Janeiro, 22270-005, Brazil
  • Research Site
    Salvador, 40301-155, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01323-900, Brazil
  • Research Site
    São Paulo, 04012-180, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Edmonton, Alberta T6G 2B7, Canada
  • Research Site
    Winnipeg, Manitoba R2H 2A6, Canada
  • Research Site
    Saint John, New Brunswick E2L 4L4, Canada
  • Research Site
    Hamilton, Ontario L8L 2X2, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    Toronto, Ontario M5B 1W8, Canada
  • Research Site
    Montreal, Quebec H1T 1C8, Canada
  • Research Site
    Montreal, Quebec H2X 0C1, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200080, China
  • Research Site
    Shenzhen, 518036, China
  • Research Site
    Shenzhen, 518053, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Zhengzhou, 450007, China
  • Research Site
    Zhengzhou, 450052, China
  • Research Site
    Bordeaux, 33074, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Montpellier, 34000, France
  • Research Site
    Toulouse, 31076, France
  • Research Site
    Frankfurt am Main, 60590, Germany
  • Research Site
    Giessen, 35392, Germany
  • Research Site
    Halle, 06120, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Jena, 07747, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Trier, 54292, Germany
  • Research Site
    Hong Kong, 999077, Hong Kong
  • Research Site
    Bangalore, 560069, India
  • Research Site
    Bangalore, 560092, India
  • Research Site
    Gūrgaon, 122001, India
  • Research Site
    Hyderabad, 500 034, India
  • Research Site
    Mysuru, 570004, India
  • Research Site
    Secunderabad, 500003, India
  • Research Site
    Haifa, 3109601, Israel
  • Research Site
    Haifa, 34362, Israel
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Milan, 20138, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Bunkyō City, 113-8431, Japan
  • Research Site
    Chūōku, 104-8560, Japan
  • Research Site
    Kamakura-shi, 247-8533, Japan
  • Research Site
    Kawasaki-shi, 216-8511, Japan
  • Research Site
    Minatoku, 105-8470, Japan
  • Research Site
    Okayama, 700-0804, Japan
  • Research Site
    Sagamihara-shi, 252-0375, Japan
  • Research Site
    Suginami City, 168-0065, Japan
  • Research Site
    Urayasu, 279-0001, Japan
  • Research Site
    Groningen, 9713 GZ, Netherlands
  • Research Site
    Maastricht, 6229 HX, Netherlands
  • Research Site
    Bielsko-Biala, 43-316, Poland
  • Research Site
    Chrzanów, 32-500, Poland
  • Research Site
    Lodz, 91-347, Poland
  • Research Site
    Lodz, 92-213, Poland
  • Research Site
    Poznan, 60-355, Poland
  • Research Site
    Szczecin, 70-111, Poland
  • Research Site
    Tychy, 43-100, Poland
  • Research Site
    Anyang-si, 14068, South Korea
  • Research Site
    Busan, 49241, South Korea
  • Research Site
    Daegu, 42601, South Korea
  • Research Site
    Seongnam-si, 13620, South Korea
  • Research Site
    Seoul, 02841, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 06351, South Korea

Showing the first 100 of 130 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ostermann M, Corteville DC, Doi K, Koyner JL, Lamy A, Li G, Solinsky CM, Winterberg PD, Smith WT, Mehta RL, Murray PT, Shaw AD, Zarbock A, Engelman DT. A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). Trials. 2025 May 30;26(1):181. doi: 10.1186/s13063-025-08895-7. PubMed 40448185 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Oct 2025, 30 months.

Results were first posted in Oct 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Feb 27, 2023
StartActual
Apr 6, 2023
Primary completionActual
Oct 7, 2025
CompletionActual
May 7, 2026
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 29, 2026
Sites
1 site added, 1 site removed
Show site
  • Research Site · Gūrgaon, India
Show 1 removed
  • Research Site · Gurgaon, India
Oct 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumberEstimated Percentage of Participants ExperiencingWho Experienced Major Adverse Kidney Events (MAKE) (, Based on serumSerum Cystatin C [sCysC)]) at Day 90 Post Cardiopulmonary Bypass-CPB (CPBMAKE90)Time frame: Day 90 post-CPB → Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Oct 29, 2026
Documents
Secondary outcomes
17 added, 1 removed
What changed in the outcomes
  • AddedEstimated Percentage of Participants With Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) Without Recovery at Day 90 Post-CPBTime frame: Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedEstimated Percentage of Participants With Severe CSA-AKI (KDIGO Stage 2 or 3)Time frame: From randomization to Days 7 and 30 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedEstimated Percentage of Participants Who Died or Required KRT From Randomization to Day 90 Post-CPBTime frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedEstimated All-cause Mortality From Randomization to Day 90 Post-CPBTime frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedEstimated Median Length of Post-operative Intensive Care Unit (ICU) StayTime frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedEstimated Percentage of Participants Who Experienced MAKE at Day 30 (MAKE30) and Day 60 (MAKE60) Post-CPB Based on sCysCTime frame: Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedEstimated Percentage of Participants Who Experienced MAKE30, MAKE60, and MAKE90 Post-CPB Based on sCrTime frame: Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedMAKE Components: Estimated Percentage of Participants Who Died From Randomization Through Days 30, 60, and 90Time frame: From randomization to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedMAKE Components: Estimated Percentage of Participants With Initiation of KRTTime frame: From randomization to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedMAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCysCTime frame: Baseline to Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedMAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCrTime frame: Baseline to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedEstimated Percentage of Participants Who Died or Required KRT From Randomization to Days 30 and 60 Post-CPBTime frame: From randomization to Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedEstimated Percentage of Participants With Post-Operative Renal FailureTime frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedNumber of Participants With Highest CSA-AKI Stage (Modified KDIGO Criteria) Based on sCrTime frame: Within 3 and 7 Days Post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedEstimated Percentage of Participants With CSA-AKI Without Recovery at Days 15, 30, and 60 Post-CPBTime frame: Days 15, 30, and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedEstimated Percentage of Participants With AKI at Days 3, 7, 15, 30, 60, and 90 Post-CPBTime frame: Days 3, 7, 15, 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • AddedNumber of Participants With AKI Progression on Days 15, 30, 60, and 90 Post-CPB for Those Experiencing CSA-AKI Within 7 Days Post-CPBTime frame: Days 15, 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
  • RemovedTo assess the efficacy of ravulizumab in reducing risk of AKI (based on sCr) following CPBTime frame: Day 90 post CPB
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Research Site · Gūrgaon, India
    Show 1 removed
    • Research Site · Gurgaon, India
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumberEstimated Percentage of Participants ExperiencingWho Experienced Major Adverse Kidney Events (MAKE) (, Based on serumSerum Cystatin C [sCysC)]) at Day 90 Post Cardiopulmonary Bypass-CPB (CPBMAKE90)Time frame: Day 90 post-CPB → Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    Secondary outcomes 17 added, 1 removed
    What changed in the outcomes
    • AddedEstimated Percentage of Participants With Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) Without Recovery at Day 90 Post-CPBTime frame: Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedEstimated Percentage of Participants With Severe CSA-AKI (KDIGO Stage 2 or 3)Time frame: From randomization to Days 7 and 30 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedEstimated Percentage of Participants Who Died or Required KRT From Randomization to Day 90 Post-CPBTime frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedEstimated All-cause Mortality From Randomization to Day 90 Post-CPBTime frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedEstimated Median Length of Post-operative Intensive Care Unit (ICU) StayTime frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedEstimated Percentage of Participants Who Experienced MAKE at Day 30 (MAKE30) and Day 60 (MAKE60) Post-CPB Based on sCysCTime frame: Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedEstimated Percentage of Participants Who Experienced MAKE30, MAKE60, and MAKE90 Post-CPB Based on sCrTime frame: Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedMAKE Components: Estimated Percentage of Participants Who Died From Randomization Through Days 30, 60, and 90Time frame: From randomization to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedMAKE Components: Estimated Percentage of Participants With Initiation of KRTTime frame: From randomization to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedMAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCysCTime frame: Baseline to Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedMAKE Components: Estimated Percentage of Participants With Decrease From Baseline in eGFR of ≥ 25% Based on sCrTime frame: Baseline to Days 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedEstimated Percentage of Participants Who Died or Required KRT From Randomization to Days 30 and 60 Post-CPBTime frame: From randomization to Days 30 and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedEstimated Percentage of Participants With Post-Operative Renal FailureTime frame: From randomization to Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedNumber of Participants With Highest CSA-AKI Stage (Modified KDIGO Criteria) Based on sCrTime frame: Within 3 and 7 Days Post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedEstimated Percentage of Participants With CSA-AKI Without Recovery at Days 15, 30, and 60 Post-CPBTime frame: Days 15, 30, and 60 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedEstimated Percentage of Participants With AKI at Days 3, 7, 15, 30, 60, and 90 Post-CPBTime frame: Days 3, 7, 15, 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • AddedNumber of Participants With AKI Progression on Days 15, 30, 60, and 90 Post-CPB for Those Experiencing CSA-AKI Within 7 Days Post-CPBTime frame: Days 15, 30, 60, and 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
    • RemovedTo assess the efficacy of ravulizumab in reducing risk of AKI (based on sCr) following CPBTime frame: Day 90 post CPB
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05746559
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Apr 6, 2023
Primary completion
Oct 7, 2025
Completion
May 7, 2026
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Study contacts

Tolga Baykal, MD, PhD
study director · +34-609-454-477

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion